Patents by Inventor Nathalie Bonnefoy-Berard

Nathalie Bonnefoy-Berard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity
    Patent number: 11685792
    Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 27, 2023
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20210261686
    Abstract: The present invention relates to a CD39 antagonist for use for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell.
    Type: Application
    Filed: December 28, 2020
    Publication date: August 26, 2021
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY
    Publication number: 20210032367
    Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.
    Type: Application
    Filed: May 21, 2020
    Publication date: February 4, 2021
    Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
  • Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity
    Patent number: 10662253
    Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: May 26, 2020
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
  • Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
    Publication number: 20160137747
    Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.
    Type: Application
    Filed: November 12, 2015
    Publication date: May 19, 2016
    Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20130273062
    Abstract: Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 17, 2013
    Applicant: OREGA BIOTECH
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
  • Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
    Publication number: 20110293629
    Abstract: The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17.
    Type: Application
    Filed: May 13, 2011
    Publication date: December 1, 2011
    Inventors: Jérémy BASTID, Nathalie BONNEFOY-BERARD, Agnés DOREAU-BASTID, Jean-François ELIAOU
  • Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
    Publication number: 20100303828
    Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.
    Type: Application
    Filed: January 30, 2009
    Publication date: December 2, 2010
    Applicant: INSERM Institut National de la Sante et de la Recherche Medicale)
    Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard